



# NUEDEXTA<sup>®</sup>

(dextromethorphan HBr and  
quinidine sulfate) capsules

20 mg

10 mg

## NUEDEXTA, FOR PATIENTS DIAGNOSED WITH PSEUDOBULBAR AFFECT

**JOHN NORTON, MD**

Director of Medical Psychiatry Inpatient Unit  
University of Mississippi Healthcare System

**Thursday, April 6, 2017 6:00 PM**

**Ruth's Chris Steakhouse**

**2058 Airport Boulevard**

**Mobile, AL 36606**

**Please RSVP to:**

**RONITA GRINDOL [rgrindol@avanir.com](mailto:rgrindol@avanir.com)**

### INDICATIONS AND USAGE

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

### IMPORTANT SAFETY INFORMATION

NUEDEXTA can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. There are not at the risk from use of NUEDEXTA. Please see additional Important Safety Information following this presentation, and see the prescriber for the Full Prescribing Information.



**AVANIR**  
pharmaceuticals